Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition

International Journal of Clinical Practice

Volumn 60, Issue 5, 2006, Pages 577-581

  Ferro, Albert ^a   Gilbert, R ^b   Krum, H ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Hypertension; Renin; Renin inhibitors

Indexed keywords

ALISKIREN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALKIREN; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOSARTAN; MINOXIDIL; MOXONIDINE; NIFEDIPINE; PERINDOPRIL; PRAZOSIN; REMIKIREN; RENIN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; MEDICAL SOCIETY; MOUSE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RAT; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33646251621     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00920.x     Document Type: Review

References (35)

1. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure. prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360: 1903-13.
3. Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10.
4. Colhoun HM, Dong W, Poulter NR. Blood pressure screening and control in England: Results from the Health Survey for England 1994. J Hypertens 1998; 16: 747-52.
5. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the health survey for England 1998. Hypertension 2001; 38: 827-32.
6. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21.
7. Ruzicka M, Leenan FHH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61: 943-54.
8. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ 1995; 311: 293-5.
9. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Pressure 2001; 10: 62-73.
10. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
11. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315: 154-9.
12. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
13. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society. Guidelines for management of hypertension: Report of the fourth Working Party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-85.
14. Neaton JD, Grimm RH Jr Prineas RJ et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270: 713-24.
15. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
16. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
17. Julius S, Kjeldsen SE, Weber M et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-31.
18. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
19. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14: 186-94.
20. Brunner HR, Laragh JH, Baer L et al. Essential hypertension. Renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-9.
21. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.
22. Attwood S, Bird R, Burch K et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 1053-60.
23. Preston RA, Materson BJ, Reda DJ et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive treatment therapy. JAMA 1998; 280: 1168-72.
24. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13.
25. Re RN. Mechanisms of disease. local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2004; 1: 42-7.
26. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389-94.
27. Oliver JA. Receptor-mediated actions of renin and prorenin. Kidney Int 2006; 69: 13-5.
28. Nguyen G, Burckle C, Sraer JD. The renin receptor: The facts, the promise and the hope. Curr Opin Nephrol Hypertens 2003; 12: 51-5.
29. Frishman WH, Fozailoff A, Lin C, Dike C. Renin inhibition: A new approach to cardiovascular therapy. J Clin Pharmacol 1994; 34: 873-80.
30. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
31. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-76.
32. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002; 39: E1-8.
33. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
34. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
35. Jeffery S. Phase 2b/3 data promising with new renin inhibitor in hypertension. theheart.org. January 25 2005. Available at http://www.theheart.org/viewArticle.do?primaryKey=384775&from=/ searchLayout.do